BR112023021015A2 - Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona - Google Patents

Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona

Info

Publication number
BR112023021015A2
BR112023021015A2 BR112023021015A BR112023021015A BR112023021015A2 BR 112023021015 A2 BR112023021015 A2 BR 112023021015A2 BR 112023021015 A BR112023021015 A BR 112023021015A BR 112023021015 A BR112023021015 A BR 112023021015A BR 112023021015 A2 BR112023021015 A2 BR 112023021015A2
Authority
BR
Brazil
Prior art keywords
morpholinoazetidin
dioxopiperidin
isoindoline
fluoro
benzyl
Prior art date
Application number
BR112023021015A
Other languages
English (en)
Inventor
Fan Wu
Michael Pourdehnad
Alves Patah Poliana
J Buchholz Tonia
Original Assignee
Bristol Myers Squibb Co
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Celgene Corp filed Critical Bristol Myers Squibb Co
Publication of BR112023021015A2 publication Critical patent/BR112023021015A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2- fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona. são fornecidos no presente documento métodos de uso de (s)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona, ou um enantiômero, uma mistura de enantiômeros, um tautômero, um isotopólogo ou um sal farmaceuticamente aceitável da mesma, em combinação com tafasitamabe, obinutuzumabe ou tazemetostate, para o tratamento, a prevenção ou o controle de linfoma não hodgkin.
BR112023021015A 2021-04-21 2022-04-20 Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona BR112023021015A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163177616P 2021-04-21 2021-04-21
PCT/US2022/025460 WO2022226011A1 (en) 2021-04-21 2022-04-20 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
BR112023021015A2 true BR112023021015A2 (pt) 2023-12-19

Family

ID=81648544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021015A BR112023021015A2 (pt) 2021-04-21 2022-04-20 Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona

Country Status (13)

Country Link
US (1) US20220362255A1 (pt)
EP (1) EP4326275A1 (pt)
JP (1) JP2024515108A (pt)
KR (1) KR20230172491A (pt)
CN (1) CN117241802A (pt)
AR (1) AR125390A1 (pt)
AU (1) AU2022263424A1 (pt)
BR (1) BR112023021015A2 (pt)
CA (1) CA3211950A1 (pt)
IL (1) IL305624A (pt)
MX (1) MX2023012294A (pt)
TW (1) TW202308644A (pt)
WO (1) WO2022226011A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2884307A1 (en) * 2012-09-07 2014-03-13 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
US11452727B2 (en) * 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
FI3784663T3 (fi) * 2018-04-23 2023-10-06 Celgene Corp Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
EP3860609A4 (en) * 2018-10-01 2022-08-03 Secura Bio, Inc. COMBINATION THERAPIES
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Also Published As

Publication number Publication date
AR125390A1 (es) 2023-07-12
JP2024515108A (ja) 2024-04-04
IL305624A (en) 2023-11-01
TW202308644A (zh) 2023-03-01
WO2022226011A1 (en) 2022-10-27
EP4326275A1 (en) 2024-02-28
US20220362255A1 (en) 2022-11-17
CA3211950A1 (en) 2022-10-27
MX2023012294A (es) 2023-10-26
AU2022263424A1 (en) 2023-09-28
CN117241802A (zh) 2023-12-15
KR20230172491A (ko) 2023-12-22

Similar Documents

Publication Publication Date Title
BR112021020372A2 (pt) Métodos de tratamento de linfoma não hodgkin ao usar 2-(2,6-dioxopiperidin-3-il)-4-((2-fluo ro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoin dolina-1,3-diona
CR20230104A (es) Compuestos y métodos para el tratamiento de infecciones virales
NO20006482L (no) 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister
BRPI0615158A8 (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
BR0308221A (pt) Derivados de tiazol e oxazol que modulam a atividade de ppar
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
DK1696931T3 (da) Amino-substituerede diaryl[A,D]cyclohepten-analoger som muskarinske agonister og fremgangsmåder til behandling af neuropsykiatriske sygdomme
EA200870128A1 (ru) Способы лечения кожной волчанки при помощи аминоизоиндолиновых соединений
NO20054607L (no) Nitrogenholdig heterosyklisk derivat som har 2,6-disubstituert styryl
AP2004003124A0 (en) Thiazole and oxazole derivatives which modulate PPAR activity
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
HK1086256A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
DE602004025698D1 (de) PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
BR0308202A (pt) Tiazóis e oxazóis substituìdos que modulam a atividade de ppar
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
AR050598A2 (es) Composicion funguicida sinergica, procedimiento para combatir hongos nocivos y uso de los compuestos que integran dicha composicion para la preparacion de dichas mezclas sinergicas
BR112019004356A2 (pt) composições de comprimido
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
BR112023021015A2 (pt) Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona
EA201592247A1 (ru) 4-(5-(4-ХЛОРОФЕНИЛ)-2-(2-ЦИКЛОПРОПИЛАЦЕТИЛ)-1,4-ДИМЕТИЛ-1H-ПИРРОЛ-3-ИЛ)БЕНЗОЛСУЛЬФОНАМИД В КАЧЕСТВЕ МОДУЛЯТОРА АЛЬФА-7 nAChR
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
BR112022007417A2 (pt) Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona
BR112023019943A2 (pt) Métodos de tratamento de linfoma de células b usando terapia combinada